Pharmacokinetics and pharmacodynamics: The role of sex and gender

Sex and Gender Aspects in Clinical Medicine

Volumn , Issue , 2013, Pages 183-194

  Franconi, Flavia ^a   Sanna, Manuela ^b   Straface, Elisabetta ^c   Chessa, Roberto ^b   Rosano, Giuseppe ^d  

^a UNIVERSITY OF SASSARI   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926399963     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-832-4_12     Document Type: Chapter

References (111)

1. Wizemann ME, Pardne M. Exploring the Biological Contributions to Human Health: Does Sex Matter? Whasington DC: National Academy of Press, 2001
2. http://w.w.w.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm120222..html.
3. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003;112:302-304.
4. Regitz-Zagrosek V. Therapeutic implications of the genderspecific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:425-439.
5. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55:81-95.
6. Testimony. National Institutes of Health: Problems in Implementing Policy on Women in Study Populations. Washington, DC: General Accounting Office; July 24, 1990. GAO/T-HRD-90-50. http://archive.gao.gov/d48t13/141859.pdf. Accessed 13 March 2008.
7. Wenger NK. Coronary heart disease in women: highlights of the past 2 years - stepping stones, milestones and obstructing boulders. Nat Clin Pract Cardiovasc Med. 2006;3:194-202.
8. http://doctor.medscape.com/viewarticle/517016.
9. Rogers W. Evidence-based medicine and women: do the principles and practice of EBM further women's health? Bioethics. 2004;18:50-71.
10. Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600, 000 older people. Ann Pharmacother. 2009;43:1233-1239.
11. Pinnow E, Sharma P, Parekh A, et al. Increasing participation of women in early phase clinical trials approved by the FDA. Womens Health Issues. 2009;19:1989-1993.
12. Heiat A, Gross CP, Krumholz HL. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
13. Office of Research on Women's Health and NHI Support for the Research on Women's Health Issue. Report for Advisory Committee on Women's Research on Women's Health; fiscal years 2005&2006 online orwh.od.nhi.gov/pubs/complete-ICD-report05-06pdf. Accessed 4 December 2008.
14. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2006;2:349-351.
15. Van Den Bemt PM, Egberts AC, Lenderink AW, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62-66.
16. Trifiro G, Calogero G, Ippolito FM, et al. Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiol Drug Saf. 2005;14:333-340.
17. Key Health Statistics from General Practice. 1998-2000 http://www.statistics. gov. uk/statbase/Product.asp?vlnk=4863. London: Office for National Statistics (last accessed 23 November 2006).
18. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18, 820 patients. BMJ. 2004;329:15-19.
19. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol. 2007;7:9. doi: 10.1186/1472-6904-7-9.
20. Leach S, Roy S. Adverse drug reactions: an investigation on an acute geriatric ward. Age Ageing. 1986;15:241-246.
21. Kurokawa J, Suzuki T, Furukawa T, et al. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci. 2009;109:334-340.
22. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
23. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
24. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143-157.
25. Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am. 1992;21:751-776.
26. Harms CA, Rosenkranz S. Sex differences in pulmonary function during exercise. Med Sci Sports Exerc. 2008;40:664-668.
27. Rohatagi S, Calic F, Harding N, et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J Clin Pharmacol. 2000;40:1211-1226.
28. Roy S, Flynn G. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharmacol Res. 1990;7:842-847.
29. Dias V, Tendler B, Oparil S, et al. Experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open label clinical trial in community-based clinics. Am J Ther. 1999;6:19-24.
30. Mattison DR. Transdermal drug absorption during pregnancy. Clin Obstet Gynecol. 1990;33:718-727.
31. Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health. 2005;14:30-37.
32. Cotreau MM, Von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33-60.
33. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989-1008.
34. Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin. 2006;22:329-345.
35. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol. 2007;47:566-578.
36. Murray M. Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opin Drug Metab Toxicol. 2007;3:185-196.
37. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci. 2007;100:7-23.
38. Hines RN, Koukouritaki SB, Poch MT, et al. Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition. Drug Metab Rev. 2008;40:263-301.
39. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
40. Yukawa E, Honda T, Ohdo S, et al. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37:92-100.
41. Dobbs NA, Twelves CJ, Gillies H, et al. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36:473-476.
42. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82:87-92.
43. Hernandez JP, Chapman LM, Kretschmer XC, et al. Gender specific induction of cytochrome P450s in nonylphenoltreated FVB/NJ mice. Toxicol Appl Pharmacol. 2006;216:186-196.
44. Wiwi CA, Gupte M, Waxman DJ. Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4a-deficient mice. Mol Endocrinol. 2004;18:1975-1987.
45. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38:978-988.
46. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193-209.
47. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157-165.
48. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1-10.
49. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-121.
50. Erratum in: Clin Pharmacokinet. 2004;43:732.
51. Doki K, Homma M, Kuga K, et al. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol. 2007;63:951-957.
52. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indianapolis: Indiana University School of Medicine; 2007. http://medicine.iupui.edu/flockhart/table.htm. Accessed 18 April 2008.
53. Thurmann PA, Haack S, Werner U, et al. Tolerability of b-blockers metabolized via cytochrome P450 2D6 is sexdependent. Clin Pharmacol Ther. 2006;80:551-553.
54. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
55. Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol. 2003;55:264-269.
56. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20:2613-2629.
57. Gorski JC, Vannaprasaht S, Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275-287.
58. Erratum in: Clin Pharmacol Ther. 2004;75:249-252.
59. Maronpot RR, Yoshizawa K, Nyska A, et al. Hepatic enzyme induction: histopathology. Toxicol Pathol. 2010;38:776-795.
60. Kawamoto T, Kakizaki S, Yoshinari K, et al. Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. Mol Endocrinol. 2000;14:1897-1905.
61. Yoshinari K, Sueyoshi T, Moore R, et al. Nuclear receptor CAR as a regulatory factor for the sexually dimorphic induction of CYP2B1 gene by phenobarbital in rat livers. Mol Pharmacol. 2001;59:278-284.
62. Schuetz E, Furuya K, Schuetz J. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275:1011-1018.
63. Masuyama H, Hiramatsu Y, Mizutani Y, et al. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol. 2001;172:47-56.
64. Adlercreutz H, Hamalainen E, Gorbach S, et al. Dietary phyto-oestrogens and the menopause in Japan. Lancet. 1992;339:1233-1236.
65. Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake and body composition in postmenopausal women. Menopause. 2003;10:427-432.
66. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005;81:397-408.
67. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-218.
68. Ochs HR, Greenblatt DJ, Divoll M, et al. Diazepam kinetics in relation to age and sex. Pharmacology. 1981;23:24-30.
69. Xue FS, Tong SY, Liao X, et al. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth Analg. 1997;85:667-671.
70. Sowinski KM, Abel SR, Clark WR, et al. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy. 1999;19:442-446.
71. Morris M, Lee H, Predko L. Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev. 2003;55:229-240.
72. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clin Pharmacokinet. 1988;15:94-113.
73. Catananti C, Liperoti R, Settanni S, et al. Heart failure and adverse drug reactions among hospitalized older adults. Clin Pharmacol Ther. 2009;86:307-310.
74. Singh S, Zoble R, Brodsky M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385-2490.
75. Saboliæ I, Asif AR, Budach WE, et al. Gender differences in kidney function. Pflugers Arch Eur J Physiol. 2007;455:397-429.
76. Gartlehner G, Chapman A, Strobelberger M, Thaler K. Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. PLoS One. 2010;5:e11895.
77. Niesters M, Dahan A, Kest B, et al. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain. 2010;151:61-68.
78. Chakrabarti S, Liu NJ, Gintzler AR. Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci USA. 2010;107:20115-20119.
79. Adamus M, Gabrhelik T, Marek O. Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium or rocuronium. Eur J Anaesthesiol. 2008;25:589-595.
80. Kaasinen V, Nagren K, Hietala J, et al. Sex differences in extrastriatal dopamine D (2)-like receptors in the human brain. Am J Psychiatry. 2001;158:308-311.
81. Xiang YT, Wang CY, Si TM, et al. Sex differences in use of psychotropic drugs and drug-induced side effects inschizophrenia patients: findings of the Research on Asia Psychotropic Prescription (REAP) studies. Aust N Z J Psychiatry. 2010;45(3):193-198.
82. Haack S, Seeringer A, Thürmann PA, et al. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10:1511-1526.
83. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. J Clin Psychiatry. 2006;59:966-974.
84. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites analyzed by critical statistics. J Clin Psychiatry. 1999;60:36-40.
85. Nich C, McCance-Katz EF, Petrakis IL, et al. Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addict Behav. 2004;29:1123-1128.
86. Serova LI, Nostramo R, Veerasirikul M, et al. Varied mechanisms of oestradiol mediated regulation of dopamine b-hydroxylase transcription. J Neuroendocrinol. 2010. doi: 10.1111/j.1365-2826.2010.02086.x.
87. Tadiæ A, Müller MJ, Rujescu D, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007;144B: 325-331.
88. Borchers AT, Keen CL, Gershwin ME, et al. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-182.
89. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
90. Ostadal B, Netuka I, Maly J, et al. Gender differences in cardiac ischemic injury and protection-experimental aspects. Exp Biol Med. 2009;234:1011-1019.
91. Malorni W, Campesi I, Straface E, et al. Redox features of the cell: a gender perspective. Antioxid Redox Signal. 2007;9:1779-1801.
92. Pretorius M, Luther JM, Murphey LJ, et al. Angiotensinconverting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol. 2005;25:2435-2440.
93. De Silva TM, Broughton BR, Drummond GR. Gender influences cerebral vascular responses to angiotensin II through Nox2-derived reactive oxygen species. Stroke. 2009;40:1091-1097.
94. Hinojosa-Laborde C, Chapa I, Lange D, et al. Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol. 1999;26:122-126.
95. Kneale BJ, Chowienczyk PJ, Brett SE, et al. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol. 2000;36:1233-1238.
96. Arias-Loza PA, Jazbutyte V, Pelzer T. Genetic and pharmacologic strategies to determine the function of estrogen receptor a and estrogen receptor b in the cardiovascular system. Gend Med. 2007;5:S34-S45.
97. Malorni W, Straface E, Matarrese P, et al. Redox state and gender differences in vascular smooth muscle cells. FEBS Lett. 2008;582:635-642.
98. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science. 2002;295:505-508.
99. Kleinert H, Wallerath T, Euchenhofer C, et al. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension. 1998;31:582-588.
100. Bae S, Zhang L. Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: focus on akt and protein kinase C signaling. J Pharmacol Exp Ther. 2005;315:1125-1135.
101. Camper-Kirby D, Welch S, Walker A, et al. Myocardial akt activation and gender: increased nuclear activity in females versus males. Circ Res. 2001;88:1020-1027.
102. Tostes RC, Fortes ZB, Callera GE, et al. Endothelin, sex and hypertension. Clin Sci. 2008;114:85-97.
103. Tsang S, Wu S, Liu J, et al. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha (1)-adrenoceptor stimulation. Br J Pharmacol. 2008;153:693-709.
104. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21:890-894.
105. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, doubleblind, placebo-controlled study. Circulation. 2000;102:1906-1911.
106. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871-874.
107. Anthony MJ. Male/female differences in pharmacology: safety issues with QT-prolonging drugs. J Womens Health (Larchmt). 2005;14:47-52.
108. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11:55-59.
109. Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011;140:818-829.
110. Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol. 2009;29:279-281.
111. Jann MW, Zum Brunnen TL, Tenjarla SN, et al. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;199:288-294.